Plasma calprotectin to assess susceptibility to bloodstream infections during paediatric acute lymphoblastic leukaemia induction treatment

British Journal of Haematology 2026 Open access

Read full text
Authors: Johanna Vævest Nymann Eriksen, Silvia De Pietri, Mathias Rathe, Henrik Hasle, Christian Enevold, Claus Henrik Nielsen, Kjeld Schmiegelow, Claus Moser, Klaus Müller, Sarah Weischendorff
DOI: 10.1111/bjh.70393
Cited by: 0

Abstract

Summary Chemotherapy‐induced neutropenia, monitored by peripheral blood absolute neutrophil count (ANC), increases the risk of bloodstream infections (BSIs). However, ANC may not reflect the total neutrophil population, as it omits neutrophils at extravascular sites. We therefore evaluated plasma calprotectin, a neutrophil‐derived protein, as a complementary marker of neutropenia severity and BSI risk. In 114 children with acute lymphoblastic leukaemia (ALL) treated according to the NOPHO ALL2008 protocol, plasma calprotectin was measured weekly during the 4‐week anthracycline‐based induction therapy. Daily ANC and BSI events were obtained from medical records. All patients developed profound neutropenia (ANC

Fields of Study & Subjects

Neutropenia and Cancer Infections Acute Lymphoblastic Leukemia research Sepsis Diagnosis and Treatment

Publication details

Journal / source
British Journal of Haematology
Volume
208
Issue
4
Pages
1339–1346
Publication date
24 February 2026
Language
EN